Epigenetics and targeted therapy in myelodysplastic syndrome: reports from the 56th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2015.03.001
- VernacularTitle:骨髓增生异常综合征表观遗传学与靶向治疗:第56届美国血液学会年会报道
- Author:
Fengru LIN
;
Jingyu ZHANG
;
Yan WANG
- Publication Type:Journal Article
- Keywords:
Myelodysplastic syndromes;
Epigenetics;
Targeted therapy;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2015;24(3):129-131
- CountryChina
- Language:Chinese
-
Abstract:
The myelodysplastic syndrome (MDS) is a clonal disorder characterized by inefficient haematopoiesis,dysplasia of hematopoietic cells in bone marrow and unable production of mature cells with normal differentiation resulting in peripheral cytopenias.The incidence of MDS is increased with the increasing age,suggesting that the accumulation of genetic or epigenetic changes lead to DNA mutations in hematopoietic stem cell,activation of oncogenes and inactivation of tumor suppressor genes,increasing limitless self-proliferation,and eventually resulting in aberrant clonal hematopoiesis and the occurrence of MDS.About thirty percentage of patients with MDS will transform into acute myeloid leukemia (AML) at last.MDS is always not sensitive to cytotoxic drugs,but targeted drugs maybe help to improve the prognosis.
